Overview
LEADING THE DISCOVERY
of Allosteric Binding Sites to Create New Medicines
Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform.
By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders.
Protein misfolding is an underlying biological issue of many diseases, including lysosomal storage disorders and some neurodegenerative diseases such as Parkinson’s disease. When a protein misfolds, its 3D structure is disrupted and it can no longer function properly. While some treatments are available for these types of disorders, they have significant limitations.
Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.
Leadership Team
 |
|
|
Eric I. Richman Chief Executive Officer |
|
| Read Bio > |
 |
|
|
Manolo Bellotto, Ph.D. General Manager and President |
|
| Read Bio > |
 |
|
|
Matthias Alder Chief Operating Officer |
|
| Read Bio > |
 |
|
|
Salvatore Calabrese Chief Financial Officer |
|
| Read Bio > |
 |
|
|
Xavier Barril, Ph.D. Chief Scientific Officer |
|
| Read Bio > |
 |
|
|
Ana Maria Garcia-Collazo, Ph.D. VP Research & Site Leader |
|
| Read Bio > |
 |
|
|
Elena Cubero-Jorda, Ph.D. Director Computational Chemistry |
|
| Read Bio > |
 |
|
|
Natália Pérez-Carmona, Ph.D. Director Biology |
|
| Read Bio > |
 |
|
|
Terenzio Ignoni, Pharm.D. SVP Quality and CMC |
|
| Read Bio > |
 |
|
|
Roberto Maj, Pharm.D. VP Development |
|
| Read Bio > |
Board of Directors
 |
|
|
Khalid Islam, Ph.D. Chairman |
|
| Read Bio > |
|
|
|
Eric I. Richman Chief Executive Officer |
|
| Read Bio > |
 |
|
|
Jeffrey Riley Independent Member |
|
| Read Bio > |
 |
|
|
Dov Goldstein, M.D. Independent Member |
|
| Read Bio > |
 |
|
|
Gwen Melincoff Independent Member |
|
| Read Bio > |
 |
|
|
Claude Nicaise, M.D. Independent Member |
|
| Read Bio > |
 |
|
|
Hans Peter Hasler Independent Member |
|
| Read Bio > |
Partners |
|
|
Research and Development Collaborations |
 |
|
Grants |
 |
 |
 |
 |
|
Patient Associations |
 |
 |
 |
 |
|
Centers of Research, Translational Science & Clinical Excellence |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Interested in working with a dynamic team of research, |